Press release
2023 Ovarian Cancer Drugs Market Research Report: Market Size, Demand, Insights and Analysis 2032 | AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Amgen Inc, Bristol-Myers Squibb Company
Ovarian Cancer Drugs Market
The increase in geriatric population is a major driver for the ovarian cancer drugs market as age is a key risk factor for ovarian cancer, with two-thirds of ovarian cancers occurring in women over the age of 55. Geriatric population often suffer with various diseases because of their age factor and most of the women aged above 65 suffer with ovarian related problems. For example, according to ACL (Administration For Community Living), a US-based government organization, the geriatric population is expected to increase by 21.6% by 2040.Therefore, increasing geriatric population will drive the ovarian cancer drugs market going forward.
View Complete Report @
https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-market
The antibody-drug conjugates or ADCs consist of a drug linked to an antibody that directly targets the cancer cell. Antibody-drug conjugates are novel therapeutic agents designed to target antigens specific to ovarian tumor cells with direct delivery of cytotoxic agents to combat recurrent, platinum-resistant disease while limiting systemic toxicity. As the field of targeted therapy continues to evolve, continued development of target antigens and ADCs are likely to represent a key development in treatment of ovarian cancer. Mirvetuximab soravtansine by ImmunoGen Inc., a US-based biotechnology company, is the only ADC that has been evaluated in a phase 3 trial. Mirvetuximab connects an antibody targeting the folate receptor alpha molecule on high-grade serous ovarian cancers to a drug molecule called DM4 that disrupts microtubule formation.
The top opportunities in the ovarian cancer drugs market segmented by drug type will arise in the alkylating agents market segment, which will gain $1,679.2 million of global annual sales by 2026. The top opportunities in the ovarian cancer drugs market segmented by tumor type will arise in the epithelial ovarian cancer market segment, which will gain $2,639.9 million of global annual sales by 2026. The top opportunities in the ovarian cancer drugs market segmented by distribution channel will arise in the drug stores market segment, which will gain $1,747.4million of global annual sales by 2026. The top opportunities in the ovarian cancer drugs market size will gain the most in USA at $1,027.6 million.
Ovarian Cancer Drugs Market Segmentation:
The Ovarian Cancer Drugs market is segmented by drug type, by tumor type and by distribution channel.
By Drug Type-
The ovarian cancer drugs market is segmented by drug type into
a) Alkylating Agents
b) Mitotic Inhibitors
c) VEGF/VEGFR Inhibitors
By Tumor Type-
The ovarian cancer drugs market is segmented by tumor type into
a) Epithelial Ovarian Cancer
b) Germ Cell Ovarian Cancer
c) Stromal Cell Ovarian Cancer
By Distribution Channel
The ovarian cancer drugs market is segmented by distribution channel into
a) Hospital Pharmacies
b) Drug Stores
c) Other Distribution Channels
Major players in the Ovarian Cancer Drugs market include AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Amgen Inc, Bristol-Myers Squibb Company.
The regions covered in the global Ovarian Cancer Drugs market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Download FREE SAMPLE Report - https://www.thebusinessresearchcompany.com/sample_request?id=8432&type=smp
The latest report from The Business Research Company, 'Global Ovarian Cancer Drugs Opportunities And Strategies Market Report - Forecast To 2032,' provides a comprehensive global perspective with data and statistics from 60+ geographies, analyzing 7000+ market segments. The regional and country breakdowns section offers insights into each geography's market analysis, size, historic and forecast growth, and key strategies for industry competitiveness.
Ovarian Cancer Drugs Market Report Table Of Content
1. Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
……
20. Pipeline Analysis
21. Key Mergers and Acquisitions
22. Opportunities And Strategies
23. Ovarian Cancer Drugs Market, Conclusions And Recommendations
24. Appendix
PURCHASE the report @
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8432
Get to know us better:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release 2023 Ovarian Cancer Drugs Market Research Report: Market Size, Demand, Insights and Analysis 2032 | AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Amgen Inc, Bristol-Myers Squibb Company here
News-ID: 3271765 • Views: …
More Releases from The Business research company
Competitive Analysis: Leading Companies and New Entrants in the Wire Arc Additiv …
The wire arc additive manufacturing cell market is rapidly gaining traction as industries increasingly embrace advanced metal 3D printing technologies. With significant investments and technological breakthroughs, this sector is set to experience remarkable growth, transforming manufacturing processes across multiple fields. Let's explore the market's size, influential players, key trends, and segmentation to understand its future trajectory.
Projected Expansion of the Wire Arc Additive Manufacturing Cell Market
The wire arc additive manufacturing cell…
Future Perspectives: Key Trends Shaping the Viscosupplementation Treatment for A …
The viscosupplementation treatment for arthritis market is on the verge of significant expansion, driven by advances in medical technology and a growing demand for effective arthritis therapies. With increasing awareness around early intervention and new treatment options, this sector is poised for rapid development over the coming years. Let's explore the market size, key players, emerging trends, and segment-wise forecasts that define this growing industry.
Projected Market Growth and Size of…
Segmentation, Major Trends, and Competitive Overview of the Viral Vector Develop …
The viral vector development service market is set to experience substantial growth in the coming years, driven by technological progress and increasing demand from various sectors. As gene therapies and advanced treatments gain prominence, the need for efficient viral vector production and development is becoming more critical. Let's explore the market size projections, key players, emerging trends, and the segment structure shaping this industry's future.
Projected Expansion and Market Size of…
Competitive Landscape: Leading Companies and New Entrants in the Transient Elast …
The transient elastography market is poised for substantial expansion as advancements in healthcare diagnostics continue to evolve. Increasing emphasis on non-invasive techniques and early disease detection is driving widespread adoption, setting the stage for strong market growth in the coming years. Let's explore the current market valuation, leading players, emerging innovations, and key segments shaping this industry.
Projected Market Value and Growth of the Transient Elastography Market
The transient elastography market is…
More Releases for Ovarian
Ovarian Cancer Diagnostics Market Size: 2033 Statistics
The Ovarian Cancer Diagnostics market is expected to grow from an estimated USD 4814.5 million in 2024 to USD 7795.1 million in 2033, at a CAGR of 5.50%.
The ovarian cancer diagnostics market plays a critical role in the early detection and management of ovarian cancer, one of the most common and lethal gynecological cancers worldwide. Ovarian cancer is often diagnosed at an advanced stage due to the lack of noticeable…
Ovarian Cancer Market Size, Future Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ovarian Cancer Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
How deadly is Ovarian Cancer?
Ovarian Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025
Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body.
The global Ovarian Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025,…
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).…
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in…
